Literature DB >> 9726238

Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells.

H Takagi1, G L King, L P Aiello.   

Abstract

Elevation of intracellular glucose within retinal vascular cells is believed to be an important causal factor in the development of diabetic retinopathy. The intracellular glucose concentration is regulated by both the rate of glucose metabolism and glucose transport. Because retinal hypoxia often precedes proliferative diabetic retinopathy, we have studied the regulation of the glucose transport system by hypoxia in cultured bovine retinal endothelial cells (BRECs). Because retinal ischemia is known to increase intracellular adenosine levels, which subsequently regulate hypoxia-inducible genes, such as vascular endothelial growth factor and erythropoietin, the role of adenosine and its receptor-mediated pathways has also been evaluated. Hypoxia (0.5% O2, 5% CO2, and 94.5% N2) stimulated GLUT1 mRNA expression in BRECs in a time-dependent manner with an 8.9 +/- 1.5-fold (P < 0.01) increase observed after 12 h. GLUT1 mRNA expression returned to baseline (1.4 +/- 0.3-fold of control) within 12 h after reinstitution of normoxia. N6-Cyclopentyl adenosine (adenosine A1 receptor agonist, Kd = 1 nmol/l) did not affect GLUT1 mRNA expression at concentrations up to 1 micromol/l, while 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamidoadenosine and 5'-(N-ethylcalboxamido)-adenosine (adenosine A2 receptor [A2R] agonists, Kd = 15 and 16 nmol/l, respectively) increased mRNA levels at concentrations as low as 10 nmol/l. Maximal stimulation was 2.3 +/- 0.2- and 2.1 +/- 0.2-fold, respectively (P < 0.01). The adenosine A2a receptor antagonist 8-(3-chlorostyryl)caffeine (CSC) (Kd = 100 nmol/l for A2R) inhibited hypoxia-stimulated GLUT1 mRNA expression by 40 +/- 8% at 100 nmo/l. Hypoxia upregulated GLUT1 protein expression by 3.0 +/- 0.3-fold after 12 h (P < 0.01), but this response was attenuated by CSC (P < 0.05). Hypoxia increased glucose transport activity by 2.1 +/- 0.3-fold (P < 0.001) after 12 h, a response inhibited 65% by CSC (P < 0.01). A protein kinase A (PKA) inhibitor (H89, 20 micromol/l) suppressed hypoxia-induced GLUT1 mRNA expression by 42 +/- 9% (P < 0.01). These data suggest that hypoxia in BRECs upregulates glucose transport activity through an increase of GLUT1 expression that is partially mediated by adenosine, A2R, and the cAMP-PKA pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726238     DOI: 10.2337/diabetes.47.9.1480

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

Review 1.  Adenosine receptors and caffeine in retinopathy of prematurity.

Authors:  Jiang-Fan Chen; Shuya Zhang; Rong Zhou; Zhenlang Lin; Xiaohong Cai; Jing Lin; Yuqing Huo; Xiaoling Liu
Journal:  Mol Aspects Med       Date:  2017-01-11

2.  Caffeine preferentially protects against oxygen-induced retinopathy.

Authors:  Shuya Zhang; Rong Zhou; Bo Li; Haiyan Li; Yanyan Wang; Xuejiao Gu; Lingyun Tang; Cun Wang; Dingjuan Zhong; Yuanyuan Ge; Yuqing Huo; Jing Lin; Xiao-Ling Liu; Jiang-Fan Chen
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

3.  Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.

Authors:  Akio Ohta; Manasa Madasu; Meenakshi Subramanian; Radhika Kini; Graham Jones; Alexander Choukèr; Akiko Ohta; Michail Sitkovsky
Journal:  Int Immunol       Date:  2013-10-22       Impact factor: 4.823

4.  Variants of the adenosine A(2A) receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes.

Authors:  Bashira A Charles; Yvette P Conley; Guanjie Chen; Rachel G Miller; Janice S Dorman; Michael B Gorin; Robert E Ferrell; Susan M Sereika; Charles N Rotimi; Trevor J Orchard
Journal:  Ophthalmic Res       Date:  2010-11-19       Impact factor: 2.892

Review 5.  Whole exome sequencing identification of novel candidate genes in patients with proliferative diabetic retinopathy.

Authors:  Cindy Ung; Angie V Sanchez; Lishuang Shen; Samaneh Davoudi; Tina Ahmadi; Daniel Navarro-Gomez; Ching J Chen; Heather Hancock; Alan Penman; Suzanne Hoadley; Mark Consugar; Carlos Restrepo; Vinay A Shah; Joseph F Arboleda-Velasquez; Lucia Sobrin; Xiaowu Gai; Leo A Kim
Journal:  Vision Res       Date:  2017-05-09       Impact factor: 1.886

6.  Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.

Authors:  Byung-Hak Kim; Junyeop Lee; Jun-Sub Choi; Dae Young Park; Ho Young Song; Tae Kyo Park; Chung-Hyun Cho; Sang-Kyu Ye; Choun-Ki Joo; Gou Young Koh; Tae-Yoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

7.  The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy.

Authors:  Xiaofeng Wang; Xiaomin Song; Wei Zhuo; Yan Fu; Hubing Shi; Yun Liang; Maomeng Tong; Guodong Chang; Yongzhang Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-24       Impact factor: 11.205

8.  Implications of glucose transporter protein type 1 (GLUT1)-haplodeficiency in embryonic stem cells for their survival in response to hypoxic stress.

Authors:  Charles Heilig; Frank Brosius; Brian Siu; Luis Concepcion; Richard Mortensen; Kathleen Heilig; Min Zhu; Richard Weldon; Guimei Wu; David Conner
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.

Authors:  Rajendra S Kadam; Preveen Ramamoorthy; Daniel J LaFlamme; Timothy A McKinsey; Uday B Kompella
Journal:  Mol Pharm       Date:  2013-05-22       Impact factor: 4.939

Review 10.  Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise.

Authors:  Emily C Keats; Zia A Khan
Journal:  Cardiovasc Diabetol       Date:  2012-04-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.